These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7877502)

  • 21. Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia.
    Colombo T; Gonzalez Paz O; D'Incalci M
    Br J Cancer; 1996 Apr; 73(7):866-71. PubMed ID: 8611397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin.
    Tsuruo T; Iida H; Yamashiro M; Tsukagoshi S; Sakurai Y
    Biochem Pharmacol; 1982 Oct; 31(19):3138-40. PubMed ID: 7150340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversal of drug sensitivity in MDR subline of P388 leukemia by gene-targeted antisense oligonucleotide.
    Nakashima E; Matsushita R; Negishi H; Nomura M; Harada S; Yamamoto H; Miyamoto K; Ichimura F
    J Pharm Sci; 1995 Oct; 84(10):1205-9. PubMed ID: 8801335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potentiation of pirarubicin cytotoxicity by dipyridamole in doxorubicin-resistant mouse P388 leukemia cells.
    Furusawa S; Fujimura T; Kawauchi H; Sasaki K; Takayanagi Y
    Res Commun Chem Pathol Pharmacol; 1991 Mar; 71(3):321-36. PubMed ID: 2047575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytofluorimetric analysis of a renal tubular cell line and its resistant counterpart.
    Rosati A; Decorti G; Klugmann FB; Candussio L; Granzotto M; Melato M; Giraldi T
    Anticancer Res; 2000; 20(5B):3403-10. PubMed ID: 11131640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced efflux of actinomycin D, vincristine, and vinblastine in adriamycin-resistant subline of P388 leukemia.
    Inaba M; Sakurai Y
    Cancer Lett; 1979 Dec; 8(2):111-5. PubMed ID: 555868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The cross resistance to cytostatics of leukemia P388 cells with induced resistance to doxorubicin].
    Donenko FV; Sitdikova SM; Kabieva AO
    Biull Eksp Biol Med; 1993 Sep; 116(9):309-11. PubMed ID: 8118011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of tunicamycin on anthracycline resistance in P388 murine leukemia cells.
    Chou TH; Kessel D
    Biochem Pharmacol; 1981 Nov; 30(22):3134-6. PubMed ID: 6950722
    [No Abstract]   [Full Text] [Related]  

  • 29. Restored in vitro sensitivity of adriamycin- and vincristine-resistant P388 leukemia with reserpine.
    Inaba M; Fujikura R; Tsukagoshi S; Sakurai Y
    Biochem Pharmacol; 1981 Aug; 30(15):2191-4. PubMed ID: 7295334
    [No Abstract]   [Full Text] [Related]  

  • 30. Electrophoretic mobility studies on doxorubicin-resistant and -sensitive murine P388 leukemic cells.
    Nair S; Horton A; Leif RC; Krishan A
    Cytometry; 1988 May; 9(3):232-7. PubMed ID: 3163971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.
    Fichtner I; Stein U; Hoffmann J; Winterfeld G; Pfeil D; Hentschel M
    Anticancer Res; 1994; 14(5A):1995-2003. PubMed ID: 7847840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Studies on a mode of resistance to m-AMSA.
    Kessel D; Wheeler C; Chou TH; Howard WS; Johnson RK
    Biochem Pharmacol; 1982 Sep; 31(18):3008-10. PubMed ID: 6897191
    [No Abstract]   [Full Text] [Related]  

  • 33. Role of protein kinase beta isozyme in multidrug resistance in murine leukemia P388/ADR cells.
    Gollapudi S; Soni V; Thadepalli H; Gupta S
    J Chemother; 1995 Apr; 7(2):157-9. PubMed ID: 7666124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin.
    Chandrasekaran B; Dimling J; Capizzi RL
    Cancer Treat Rep; 1987 Feb; 71(2):195-6. PubMed ID: 2948640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Active efflux common to vincristine and daunorubicin in vincristine-resistant P388 leukemia.
    Inaba M; Fujikura R; Sakurai Y
    Biochem Pharmacol; 1981 Jul; 30(13):1863-5. PubMed ID: 7271878
    [No Abstract]   [Full Text] [Related]  

  • 36. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
    Ganapathi R; Grabowski D; Schmidt H; Seshadri R; Israel M
    Biochem Biophys Res Commun; 1985 Sep; 131(2):912-9. PubMed ID: 2932108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Assay of flow cytometry for the effect of cepharanthine on resistance to doxorubicin].
    Kisara S; Hayashi A; Maekawa I; Furusawa S; Takayanagi Y; Sasaki K
    Yakugaku Zasshi; 1992 Nov; 112(11):837-45. PubMed ID: 1484349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
    Tsuruo T; Oh-Hara T; Sudo Y; Naito M
    Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Membrane transport changes in an adriamycin-resistant murine leukemia cell line and in its sensitive parental cell line.
    Bose R; Lam HY
    Cancer Chemother Pharmacol; 1988; 21(1):14-8. PubMed ID: 3342461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with a special emphasis on quinacrine.
    Inaba M; Maruyama E
    Cancer Res; 1988 Apr; 48(8):2064-7. PubMed ID: 3349478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.